| Title | Immunopathology and the gene therapy of lupus. | | Author(s) | Mageed RA, Prud'homme GJ | | Institution | Department of Immunology and Molecular Pathology, Royal Free and University College School of Medicine, London, UK. | | Source | Gene Ther 2003 May; 10(10):861-74. | | MeSH | Animals
Antigen-Antibody Complex
Antigens, CD
Antigens, Differentiation
Autoantibodies
B-Lymphocytes
Complement System Proteins
Cytokines
Disease Models, Animal
Gene Therapy
Gene Transfer Techniques
Genetic Predisposition to Disease
Humans
Immunoconjugates
Immunotherapy
Killer Cells, Natural
Lupus Erythematosus, Systemic
Mice
Phagocytosis
T-Lymphocytes
Transforming Growth Factor beta
| | Abstract | Lupus is a chronic autoimmune inflammatory disease with complex clinical manifestations. In humans, lupus, also known as systemic lupus erythematosus (SLE), affects between 40 and 250 individuals, mostly females, in each 100 000 of the population. There are also a number of murine models of lupus widely used in studies of the genetics, immunopathology, and treatment of lupus. Human patients and murine models of lupus manifest a wide range of immunological abnormalities. The most pervasive of these are: (1) the ability to produce pathogenic autoantibodies; (2) lack of T- and B-lymphocyte regulation; and (3) defective clearance of autoantigens and immune complexes. This article briefly reviews immunological abnormalities and disease mechanisms characteristic of lupus autoimmunity and highlight recent studies on the use of gene therapy to target these abnormalities. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review
| | PubMed ID | 12732872 |
|
